linaclotide: Clinical Trials

13 trials of linaclotide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 1 active not recruiting, 1 terminated. 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 213Completed 11, Active not recruiting 1, Terminated 1

Follow linaclotide: new trials by email Literature Review of linaclotide trials Research Report on linaclotide

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
Linaclotide, Placebo - Functional Constipation
Phase 2CompletedAbbVie192023-04-272026-01-06
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
Linaclotide, Placebo - Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8
Phase 2Active not recruitingSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1502019-10-302026-10-08
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
Linaclotide, Placebo - Functional Constipation
Phase 2CompletedAllergan352019-10-142022-04-26
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
Placebo, LIN Dose A, LIN Dose B - Functional Constipation in Children Ages 6-17 Years
Phase 2CompletedForest Laboratories1732015-11-032019-06-19
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C - Irritable Bowel Syndrome With Constipation
Phase 2TerminatedForest Laboratories1012015-11-012020-12-28
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Linaclotide, Matching Placebo - Irritable Bowel Syndrome With Constipation
Phase 2CompletedIronwood Pharmaceuticals, Inc.7592015-10-222020-04-24
A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation
ASP0456, Placebo - Chronic Constipation
Phase 2CompletedAstellas Pharma Inc3832015-04-132024-10-18
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo - Opioid-Induced Constipation
Phase 2CompletedForest Laboratories2542014-10-312019-04-08
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
linaclotide, placebo - Constipation-predominant Irritable Bowel Syndrome (IBS-C)
Phase 2CompletedAstellas Pharma Inc5592012-08-102024-10-18
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Linaclotide Acetate, Matching placebo - Irritable Bowel Syndrome With Constipation
Phase 2CompletedIronwood Pharmaceuticals, Inc.4202007-04-012013-02-04
Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
linaclotide acetate, Matching placebo - Chronic Constipation
Phase 2CompletedIronwood Pharmaceuticals, Inc.3102006-11-012013-03-05
Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
MD-1100 Acetate - Constipation
Phase 2CompletedIronwood Pharmaceuticals, Inc.402006-03-012009-03-24
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
MD-1100 Acetate - Irritable Bowel Syndrome
Phase 2CompletedIronwood Pharmaceuticals, Inc.362006-01-012006-10-20

Conditions studied

Constipation (3)  ·  Irritable Bowel Syndrome (3)  ·  Colorectal Neoplasms (1)  ·  Opioid-Induced Constipation (1)

Sponsors

Ironwood Pharmaceuticals, Inc. (5)  ·  Forest Laboratories (3)  ·  Astellas Pharma Inc (2)  ·  AbbVie (1)  ·  Allergan (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)

Countries

United States (11)  ·  Canada (3)  ·  Japan (2)  ·  Bulgaria (1)  ·  Croatia (1)  ·  Germany (1)  ·  Hungary (1)  ·  Serbia (1)  ·  United Kingdom (1)

Top investigators

Anna Muslin (2)  ·  Jeffrey M. Johnston, MD, FACP (1)  ·  Michael Camilleri, MD (1)  ·  Patricia D'Astoli, RN (1)  ·  Paul Chamberlin, MD (1)  ·  Scott Waldman, MD (1)  ·  Taryn Weissman (1)

Results publications

PMID 20045700, PMID 20801122, PMID 30084233, PMID 32310620, PMID 33065589, PMID 36324245, PMID 38504394, PMID 38962910

NIH funding

2019 (1)